SBMFF (Sino Biopharmaceutical) Other Long Term Assets : $3,953 Mil (As of Jun. 2024)

View and export this data going back to 2010. Start your Free Trial

What is Sino Biopharmaceutical Other Long Term Assets?

Sino Biopharmaceutical's other long-term assets for the quarter that ended in Jun. 2024 was $3,953 Mil.

Sino Biopharmaceutical's quarterly other long-term assets increased from Jun. 2023 ($3,650 Mil) to Dec. 2023 ($3,778 Mil) and increased from Dec. 2023 ($3,778 Mil) to Jun. 2024 ($3,953 Mil).

Sino Biopharmaceutical's annual other long-term assets declined from Dec. 2021 ($4,210 Mil) to Dec. 2022 ($3,868 Mil) and declined from Dec. 2022 ($3,868 Mil) to Dec. 2023 ($3,778 Mil).

Sino Biopharmaceutical Other Long Term Assets Historical Data

The historical data trend for Sino Biopharmaceutical's Other Long Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sino Biopharmaceutical Other Long Term Assets Chart

Sino Biopharmaceutical Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Other Long Term Assets

Get a 7-Day Free Trial

2,295.41

4,209.59

3,867.60

3,778.35

3,759.75

Sino Biopharmaceutical Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Other Long Term Assets	Get a 7-Day Free Trial															3,867.60	3,649.80	3,778.35	3,953.39	3,759.75

Sino Biopharmaceutical Other Long Term Assets Calculation

GuruFocus lists Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets under the "Total Long-Term Assets" section.

Other Long Term Assets includes following items:
Investment in Properties
Non-current Accounts Receivable
Non-current Note Receivables
Non-current Deferred Assets
Non-current Prepaid Assets
Defined Pension Benefit
Other (too numerous to list)
Some companies can do choose to report each of these items separately. Yet, there are a variety of Other Long Term Assets which are simply too numerous to list.

Sino Biopharmaceutical Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sino Biopharmaceutical Ltd (OTCPK:SBMFF) » Definitions » Other Long Term Assets

Comparable Companies

Traded in Other Exchanges

SBHMY:USA 01177:Hong Kong SMZ1:Germany SMZ1:Germany

Address

1 Harbour Road, Unit 09, 41st Floor, Office Tower, Room 4109, Convention Plaza, Wanchai, Hong Kong, HKG

Website

https://www.sinobiopharm.com

Listed on the Hong Kong Stock Exchange in 2000, Sino Biopharmaceutical is one of the largest Chinese drugmakers. It started with generic drug manufacturing. Since 2018, Sino Biopharm has been actively pivoting into an innovative drugmaker after the Chinese government launched its volume-based procurement policy for the healthcare industry. As of 2023, 37.8% of the firm's total revenue comes from five innovative drugs and five biosimilar drugs. Sino Biopharm's biggest revenue segment is oncology medicines, accounting for 33.6% of total revenue, followed by hepatitis, surgery/analgesia, respiratory, and cardio-cerebral vascular therapeutic areas.